Rocket Pharmaceuticals, Inc. is a late-stage biotechnology company developing genetic therapies for complex and rare disorders. Its lentiviral vector-based gene therapies target hematologic diseases, including late-stage programs for Fanconi Anemia, Leukocyte Adhesion Deficiency-I, and Pyruvate Kinase Deficiency. The company also has in vivo adeno-associated virus programs in clinical and pre-clinical stages for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy, and BAG3 Dilated Cardiomyopathy. The RCKT YTD return is shown above.
The YTD Return on the RCKT YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether RCKT YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the RCKT YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|